Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine - Wikidata - wikimedia - TriplyDB

Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine

Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine

http://www.wikidata.org/entity/Q34419681

about

Current understanding of interactions between nanoparticles and the immune system Novel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches Nanotechnology: Future of Oncotherapy Nanoparticle contrast agents for computed tomography: a focus on micelles Immunosuppressive and anti-inflammatory properties of engineered nanomaterials Nanomedicine therapeutic approaches to overcome cancer drug resistance The big picture on nanomedicine: the state of investigational and approved nanomedicine products Cancer nanotechnology: emerging role of gold nanoconjugates Stimulating antitumor immunity with nanoparticles Detecting and destroying cancer cells in more than one way with noble metals and different confinement properties on the nanoscale Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.High-Density Lipoproteins: Nature's Multifunctional Nanoparticles Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro Nanotechnologies for noninvasive measurement of drug release Evaluation of uptake and distribution of gold nanoparticles in solid tumors The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery Nanotechnology in respiratory medicine Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates Clinical Translation of Nanomedicine.Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?Nanotechnology in the war against cancer: new arms against an old enemy - a clinical view.All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model.On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles.Multifunctional gold nanoparticles for diagnosis and therapy of disease Nanoparticles for Improving Cancer Diagnosis.Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics.Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality.High-resolution contrast-enhanced optical coherence tomography in mice retinae Potential applications and human biosafety of nanomaterials used in nanomedicine In vivo imaging of nanoparticle delivery and tumor microvasculature with multimodal optical coherence tomography Synthesis and patterning of tunable multiscale materials with engineered cells.Curcuma mangga-Mediated Synthesis of Gold Nanoparticles: Characterization, Stability, Cytotoxicity, and Blood Compatibility.Update on current and potential nanoparticle cancer therapies Modifying Dendritic Cell Activation with Plasmonic Nano Vectors Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro.Thermophysical and biological responses of gold nanoparticle laser heating.P-glycoprotein-dependent trafficking of nanoparticle-drug conjugates

P2860

Q26345204-B590A3AB-E4CC-45D6-A6FC-B78513E4B0F6 Q26767185-A2270F6A-1203-4E6A-A32E-500EC749986C Q26795570-C42A1460-FE75-4601-B44E-906B8AB24225 Q26801067-69D6288D-046F-492A-AA9A-C5C5E6EDC295 Q26863316-B2DF9268-1D6F-4DEB-8CF6-606B7B0FFF52 Q27005267-75286A36-F8F1-498C-9A99-209BA6C6CC96 Q27011692-248C7ADE-F446-4414-93C3-649BDDEB9C29 Q27021817-7FD1DC10-17D7-4E53-90A8-4DC301339F0A Q27021820-B26AF740-017A-4771-B30E-74BE566CFE94 Q27027780-A7B5A199-AAAF-4EC1-AD6A-8673565D1B6A Q27339930-A4164F9C-C4A4-4622-A615-DD63168B423F Q28073956-DD14F957-E931-47E1-96CC-E1529263C338 Q28077290-2E7B8A34-DAF1-4F2A-A276-57E7B95C3EF0 Q28081577-05F1B07C-F565-443C-ADDF-58D59E9177B2 Q28385413-FF904D23-30C2-4DEB-9107-15426995A882 Q28387499-CEF47BB3-A087-4FC2-9D2B-B501F4244D97 Q28390095-283CF886-A0FE-4593-BD0C-F1E3C566E90E Q28392595-714A5BF6-4219-4639-B646-26D426743850 Q28395660-6F0695A6-D7A7-49E6-92CE-14D1CC185E06 Q28553214-F39C6E45-E5B6-41FD-A132-0AD6F09B0169 Q30355939-2F59271E-5AC0-4E01-A1C4-564D06807AEE Q30360668-4CEACAE8-61E2-468B-B525-EE84DC723AC4 Q30376531-E2F80C33-4BD1-4768-8449-9DB11BECADA4 Q30387995-902D1E97-9544-43AA-920A-1C7E59013761 Q30390899-0BE87098-075C-4DC5-BC5E-8B340F396385 Q30407976-8B54D081-1717-4F59-BC9C-16B3741BD289 Q30442090-803A761C-1369-4B26-8F50-1AB9FC9F5F4D Q30442412-1255861F-4376-4B44-AB1D-485EDAAF6C94 Q30457900-5C29BDDA-D635-4228-BD9F-1B223FC4FABA Q30585395-A17A5C6E-B066-4E5D-8B39-4C2B5FDB9D1B Q30766004-5202248E-B41A-403C-B2B2-0381F76B0D19 Q32944368-EF9DBD91-CF6C-4C7B-AA86-F1D1C32C6FCA Q33738557-6693584A-1138-44B3-AFA0-5C7B5C750F25 Q33777722-8ABFEF60-545C-4F08-982A-9F17256880C5 Q33837858-029F2692-B4D9-442F-878A-7138875FDD5B Q33874239-98F935FC-86E9-4D23-A485-C01F6C30BDD8 Q33906222-65CC2757-8C14-4042-80DD-C4332CCAA32E Q33918636-EC90DF10-12CF-4229-8710-E2B48616C797 Q34030504-414F2E80-86CE-43BD-88AC-21D1327B0DC2 Q34062299-977EFD68-3B05-4216-B2B8-B6C5E0919534

P2860

Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine

http://www.wikidata.org/entity/Q34419681

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@ast

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@en

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@nl

type

label

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@ast

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@en

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@nl

prefLabel

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@ast

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@en

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@nl

P1433

Q34419681-2E931521-AF39-4285-ABD5-140351E75668

P1476

Q34419681-3997ECE8-9F36-4B51-9F62-A9F60DB1F7BF

P2093

Q34419681-004B8960-F54C-419C-BE9E-CD9B48E4BC5F

Q34419681-04B67F4C-0D2C-4939-B008-BC6EE116D109

Q34419681-0827D3FC-8B90-4DEF-8FCE-8B177121EDBF

Q34419681-087D33A3-C0B9-4D0D-9A02-BC3BA1363B59

Q34419681-21B8290F-9F3E-459B-9D08-457A2018F21D

Q34419681-57B50469-5C32-4DEE-BF16-A8BADE8675F2

Q34419681-9BCDAB93-5341-4CBF-8FAC-68495825B6DF

Q34419681-9EDFB3C0-3D4D-45FB-BFB0-DCB0756836E3

Q34419681-DF870D11-A55E-4A56-A600-B086C6C52890

P2860

Q34419681-09194E2D-0E16-480C-9345-E1FEF258B2E3

Q34419681-0B746712-2EBA-47EB-BCD5-B34E04C49585

Q34419681-0DAE5ABF-A0C8-42E4-B69E-543099EDD698

Q34419681-1F60DA10-A491-4CF3-A395-9A6411AAA05C

Q34419681-21B9C22F-7335-4F74-992D-C43B8DA1063B

Q34419681-2C342180-091D-409F-A304-6EB2935B4D6F

Q34419681-2D2B2650-0A1C-427A-B610-8A1D3C8C9264

Q34419681-2F728B1D-FA58-4B67-9CCC-FFB59D236107

Q34419681-474262DC-EA4E-45B7-8FB6-525EF088BBCE

Q34419681-65697163-1DF6-4EBC-B1DC-E7B75072447E

P304

Q34419681-9AEB9212-D240-4AF7-A27E-E283DB81CD44

P31

Q34419681-4F25EE1B-0C47-4F48-B38A-B334CF5790DD

P356

Q34419681-3545DCA5-EB5F-4724-B2F4-B19CE582AEFD

P407

Q34419681-C999D9D6-CD35-4496-9AC9-434AE52D8ECF

P433

Q34419681-E6A53470-5645-4D8E-833E-EDF7E5F1A926

P478

Q34419681-C81AAD65-83F4-4E30-A799-69274E43526B

P577

Q34419681-C7D908D7-13EF-47D6-9C37-568AFFF6DCBF

P698

Q34419681-BCCD626F-89D1-46F7-870E-D16535B98086

P921

Q34419681-E0602483-864E-4320-8858-9D5EBBF7C300

P932

Q34419681-BB1399A3-3C29-4F2D-881C-3792D7CCE7AD

P356

1078-0432.CCR-10-0978

P1433

Clinical Cancer Research

P1476

Phase I and pharmacokinetic st ...... loidal gold-rhTNF nanomedicine

@en

P2093

Adriana A Byrnes

http://www.w3.org/2001/XMLSchema#string

Geoffrey D Seidel

http://www.w3.org/2001/XMLSchema#string

Giulio F Paciotti

http://www.w3.org/2001/XMLSchema#string

H Richard Alexander

http://www.w3.org/2001/XMLSchema#string

Lawrence Tamarkin

http://www.w3.org/2001/XMLSchema#string

Melissa Walker

http://www.w3.org/2001/XMLSchema#string

Nargiza Yuldasheva

http://www.w3.org/2001/XMLSchema#string

Steven K Libutti

http://www.w3.org/2001/XMLSchema#string

William E Gannon

http://www.w3.org/2001/XMLSchema#string

P2860

An endotoxin-induced serum factor that causes necrosis of tumors

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

Phase I study of recombinant human tumor necrosis factor.

Translational considerations for cancer nanomedicine.

Shock and tissue injury induced by recombinant human cachectin.

Solid tumor therapy: manipulation of the vasculature with TNF.

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system.

P304

6139-6149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0978

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20876255

http://www.w3.org/2001/XMLSchema#string

P921

P932

3004980

http://www.w3.org/2001/XMLSchema#string